Open AccessUse of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study
Author(s) -
Kendra K Radtke,
Peter Bacchetti,
Kathryn Anastos,
Daniel Merenstein,
Howard Crystal,
Roksana Karim,
Kathleen M. Weber,
Andrew Edmonds,
Anandi N. Sheth,
Margaret A. Fischl,
David E. Vance,
Ruth M. Greenblatt,
Leah H. Rubin
Publication year - 2018
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000001658
Subject(s) - medicine , neurocognitive , context (archaeology) , odds ratio , confidence interval , comorbidity , depression (economics) , cohort study , prospective cohort study , cohort , serostatus , adverse effect , psychosocial , human immunodeficiency virus (hiv) , psychiatry , viral load , immunology , cognition , paleontology , economics , biology , macroeconomics
Neurocognitive impairment is a frequent and often disabling comorbidity of HIV infection. In addition to antiretroviral therapies, individuals with HIV infection may commonly use nonantiretroviral medications that are known to cause neurocognitive adverse effects (NC-AE). The contribution of NC-AE to neurocognitive impairment is rarely considered in the context of HIV and could explain part of the variability in neurocognitive performance among individuals with HIV.